WO2000025766A3 - Use of nk antagonist for treating gastric asthma - Google Patents

Use of nk antagonist for treating gastric asthma Download PDF

Info

Publication number
WO2000025766A3
WO2000025766A3 PCT/GB1999/003536 GB9903536W WO0025766A3 WO 2000025766 A3 WO2000025766 A3 WO 2000025766A3 GB 9903536 W GB9903536 W GB 9903536W WO 0025766 A3 WO0025766 A3 WO 0025766A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
treating gastric
gastric asthma
asthma
neurokinin
Prior art date
Application number
PCT/GB1999/003536
Other languages
French (fr)
Other versions
WO2000025766A2 (en
Inventor
David John Lengel
William Leroy Rumsey
Original Assignee
Astrazeneca Ab
David John Lengel
William Leroy Rumsey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, David John Lengel, William Leroy Rumsey filed Critical Astrazeneca Ab
Priority to AU63571/99A priority Critical patent/AU6357199A/en
Publication of WO2000025766A2 publication Critical patent/WO2000025766A2/en
Publication of WO2000025766A3 publication Critical patent/WO2000025766A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Use of neurokinin 2 (NK2) receptor antagonists in the treatment or prevention of gastric asthma or adverse respiratory events associated with gastroesophageal reflux, including pharmaceutical compositions containing the NK2 receptor antagonist and methods for making such compositions.
PCT/GB1999/003536 1998-10-30 1999-10-26 Use of nk antagonist for treating gastric asthma WO2000025766A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63571/99A AU6357199A (en) 1998-10-30 1999-10-26 Treatment of gastric asthma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10635498P 1998-10-30 1998-10-30
US60/106,354 1998-10-30

Publications (2)

Publication Number Publication Date
WO2000025766A2 WO2000025766A2 (en) 2000-05-11
WO2000025766A3 true WO2000025766A3 (en) 2000-09-21

Family

ID=22310952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/003536 WO2000025766A2 (en) 1998-10-30 1999-10-26 Use of nk antagonist for treating gastric asthma

Country Status (3)

Country Link
AU (1) AU6357199A (en)
GB (1) GB9924141D0 (en)
WO (1) WO2000025766A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9911017D0 (en) * 1999-05-13 1999-07-14 Zeneca Ltd Pharmaceutical compositions
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence
EP1352659A4 (en) * 2000-12-22 2004-06-30 Takeda Chemical Industries Ltd Combination drugs
SE0103795D0 (en) * 2001-11-02 2001-11-02 Astrazeneca Ab Compounds and method for the treatment of overactive bladder
SE0103668D0 (en) * 2001-11-02 2001-11-02 Astrazeneca Ab Method for the treatment of overactive leaves
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
WO2006121389A1 (en) * 2005-05-10 2006-11-16 Astrazeneca Ab Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity
AR057828A1 (en) 2005-09-29 2007-12-19 Astrazeneca Ab COMPOUNDS DERIVED FROM AZETIDINE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITION
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625509A1 (en) * 1993-05-17 1994-11-23 Zeneca Limited N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity
EP0630887A1 (en) * 1993-05-24 1994-12-28 Zeneca Limited 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists
WO1995005377A1 (en) * 1993-08-17 1995-02-23 Zeneca Limited Heterocycles useful as neurokinin antagonists
WO1995012577A1 (en) * 1993-11-03 1995-05-11 Zeneca Limited Novel 4-piperidinyl substituted lactames as neurokinin 2 receptor antagonists for the treatment of asthma
WO1997027185A1 (en) * 1996-01-22 1997-07-31 Pfizer Research And Development Company, N.V./S.A. Piperidone tachykinin antagonists
EP0791592A2 (en) * 1996-01-27 1997-08-27 Pfizer Limited Azetidines
US5697112A (en) * 1996-11-08 1997-12-16 Glaxo Wellcome Inc. Therapy pillow useful for treating gastroesophageal reflux disease (gerd) and other applications

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625509A1 (en) * 1993-05-17 1994-11-23 Zeneca Limited N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity
EP0630887A1 (en) * 1993-05-24 1994-12-28 Zeneca Limited 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists
WO1995005377A1 (en) * 1993-08-17 1995-02-23 Zeneca Limited Heterocycles useful as neurokinin antagonists
WO1995012577A1 (en) * 1993-11-03 1995-05-11 Zeneca Limited Novel 4-piperidinyl substituted lactames as neurokinin 2 receptor antagonists for the treatment of asthma
WO1997027185A1 (en) * 1996-01-22 1997-07-31 Pfizer Research And Development Company, N.V./S.A. Piperidone tachykinin antagonists
EP0791592A2 (en) * 1996-01-27 1997-08-27 Pfizer Limited Azetidines
US5697112A (en) * 1996-11-08 1997-12-16 Glaxo Wellcome Inc. Therapy pillow useful for treating gastroesophageal reflux disease (gerd) and other applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAVURU: "medical treatment...", GASTROESOPHAGEAL REFLUX DISEASE AND AIRWAY DISEASE, - 1999, pages 179 - 203, XP000920806 *
MAYS: "Intrinsic asthma in adults", E.E.JAMA, vol. 236, no. 23, 1976, pages 2626, XP000914287 *

Also Published As

Publication number Publication date
GB9924141D0 (en) 1999-12-15
WO2000025766A2 (en) 2000-05-11
AU6357199A (en) 2000-05-22

Similar Documents

Publication Publication Date Title
EP0715855A3 (en) NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
MXPA05002442A (en) Imidazolopyridines and methods of making and using the same.
WO2002053180A3 (en) Immunizing compositions and methods of use
LT2001004A (en) Fertilizer from sapropel and manufacture thereof
HK1008819A1 (en) Piperidine derivatives as neurokinin antagonists
CA2424664A1 (en) Novel non-imidazole compounds
CY2567B1 (en) Treatment of normotensive glaucoma with angiotensin II antagonists
WO1996017869A3 (en) Interleukin-6 (il-6) antagonists
HU9503826D0 (en) Heterocycles useful as neurokinin antagonists
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
HUP0400349A3 (en) Ccr5 antagonists useful for treating aids and pharmaceutical compositions containing them
WO1999024051A3 (en) Application of vasopressin antagonists for treating disturbances or illnesses of the inner ear
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
BG105256A (en) Muscarinic agonists and antagonists
BR0311898A (en) Combination treatment for depression and anxiety with nk1 and nk3 antagonists
WO2000025766A3 (en) Use of nk antagonist for treating gastric asthma
WO1999038532A3 (en) Methods for the prevention and treatment of fibrosis and sclerosis
GR3030626T3 (en) 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
EP1186318A3 (en) Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
DK0636027T3 (en) Angiotensin II Antogonists for Disorders Associated with Impaired Neuronal Conduction Rate, especially Diabetic Neuropathy
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 63571

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase